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Background: Triplication is a rare chromosomal anomaly. We identified a de novo triplication of 11q12.3 in a
patient with developmental delay, distinctive facial features, and others. In the present study, we discuss the
mechanism of triplications that are not embedded within duplications and potential genes which may contribute
to the phenotype.
Results: The identified triplication of 11q12.3 was 557 kb long and not embedded within the duplicated regions.
The aberrant region was overlapped with the segment reported to be duplicated in 2 other patients. The common
phenotypic features in the present patient and the previously reported patient were brain developmental delay,
finger abnormalities (including arachnodactuly, camptodactyly, brachydactyly, clinodactyly, and broad thumbs), and
preauricular pits.
Conclusions: Triplications that are not embedded within duplicated regions are rare and sometimes observed as
the consequence of non-allelic homologous recombination. The de novo triplication identified in the present study
is novel and not embedded within the duplicated region. In the 11q12.3 region, many copy number variations
were observed in the database. This may be the trigger of this rare triplication. Because the shortest region of
overlap contained 2 candidate genes, STX5 and CHRM1, which show some relevance to neuronal functions, we
believe that the genomic copy number gains of these genes may be responsible for the neurological features seen
in these patients.
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Triplication is a rare chromosomal aberration. Many
chromosomal triplications that are visible by conventional
karyotyping have been reported. Such chromosomal
rearrangements are considered to be caused by abnormal
meiotic chromosomal recombinations [1,2]. The introduc-
tion of chromosomal microarray testing allowed the identi-
fication of invisible small triplications. Although we have
performed chromosomal microarray testing of >1,000
samples in our institution, only 3 invisible triplications have
been identified to date (Figure 1). Thus, the frequency of* Correspondence: yamamoto.toshiyuki@twmu.ac.jp
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distribution, and reproduction in any mediumsuch triplications is <0.3% in patients with developmental
delay and/or congenital abnormalities.
When we analyzed genomic copy numbers in cases of
triplication, the patterns of the results could be classified
into 2 types according to genomic structures: (1) embedded
within the duplicated segments and (2) not embedded
within the duplicated segments (Figure 1). Two of the 3
triplications in our laboratory were embedded within the
duplicated regions. A triplication identified at 17p13.3,
including the platelet-activating factor acetylhydrolase 1b
regulatory subunit 1 gene (PAFAH1B1) (a gene responsible
for lissencephaly) was among them [3] (Figure 1). The
triplicated segment was embedded within the duplicated
regions, and fiber-fluorescence in situ hybridization (FISH)
analysis confirmed that the triplicated segments were in atral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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Figure 1 Explanation of the 2 triplication patterns. Each triplication pattern shown by Gene View of Agilent Genomic Workbench (Agilent
Technologies) is schematically represented. The blue rectangles indicate chromosomal aberrations. The X- and Y- axes indicate the genomic
location and a log2 ratio of the intensity, respectively. The log2 ratio of the triplicated region is 2-fold higher than that of the duplicated region.
(A) The triplication embedded within the duplication region shows duplicated regions (dup) in both ends of the triplication (tri). The 2 examples
at 17p13.2 and Xq22.1 include PAFAH1B1 and PLP1, respectively. (B) The triplication not embedded within the duplicated region does not show
any duplicated regions on either end of the triplication (tri) Two examples of duplication and triplication at Xp22.31 that include STS are shown.
Both aberrations show the same range of the aberration. There are no duplicated regions around the triplicated segment. The black rectangles
indicate the locations of the genes.
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was also reported by Bi et al.; however, the nucleotide
sequence of the breakpoints and/or inserted orientation
was not analyzed [4]. Although breakpoint junctions have
been analyzed in many cases with chromosomal re-
arrangements [5], it is challenging to map and sequence
them in cases of copy number gains due to the existence of
extra copies of the fragments, particularly in the case of
autosomal chromosomes [6].
Another triplication embedded within the duplicated
segments was identified in a patient with Pelizaeus-
Merzbacher disease [7] (Figure 1), whose triplication,
including the proteolipid protein 1 gene (PLP1), was caused
by the mechanism of duplication-inverted triplication-
duplication (DUP-TRP/INV-DUP). This mechanism was
first reported by Carvalho et al. as the common mechanism
in patients with recurrent triplication around the methyl
CpG binding protein 2 gene (MECP2) located on Xq28 [8].
The third triplication identified in the Xp22.31 region
was not embedded within the duplicated segments, and
the aberration region was same as the duplication that is
well-known as a popular copy number variation (CNV)
(Figure 1). This triplication, including the steroid sylfatase
gene (STS), was previously reported as not being embedded
within the duplicated segments because the breakpoints
were common among aberrations identified in individuals[6]. This finding indicated that non-allelic homologous re-
combination (NAHR) is mediated by low copy repeats
(LCRs) surrounding the triplicated structures in this region,
the orientation of the inserted triplicated segments remain
unknown in those cases.
As mentioned above, a triplication embedded within a
duplication is common in cases of random occurrences;
however, triplications that are not embedded within
duplicated regions may be caused by surrounding LCRs
as a consequence of NAHR. In this study, we identified
a de novo triplication that was not embedded within a
duplication, in a patient with developmental delay and
distinctive features. Herein, we discuss the genotype-
phenotype correlation as well as the mechanism of
chromosomal triplication.
Case report
A 22-month-old girl was born at 38 weeks of gestation,
and she was the third child of healthy parents. Her birth
weight was 2,714 g (10~25 centile), length was 46.5 cm
(10~25 centile), and occipitofrontal circumference
(OFC) was 34.1 cm (75~90 centile). Her father and
mother were 37 and 35 years old, respectively. At birth,
low-set ears were noted. From early infancy, she showed
feeding difficulty because of hypotonia and hypersomnia.
Early development was delayed, with head control at 5
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crawling at 13 months, and standing unsupported at 22
months. Brain magnetic resonance imaging, electroen-
cephalography, and auditory brainstem response did not
show any abnormalities.
At present, her height is 82.1 cm (10~25 centile), weight
is 11.2 kg (50~75 centile), and OFC is 45.4 cm (10~25
centile). She has distinctive facial features, including
midface hypoplasia, a flat nasal bridge, telecanthus,
anteverted nares, a small nose, long philtrum, low-set and
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MRI magnetic resonance imaging; EEG electroencephalogram; ABR auditory brain recups, a right preauricular pit, thin lips, a high arched
palate, and micrognathia. Arachnodactyly is also
noted. Neurological examination reveals generalized
hypotonia and right esotropia (Table 1).
Results
The conventional G-banding technique showed a normal
female karyotype of 46,XX. By use a 60K array, a gain of
the genomic copy number was identified on the 11q12.3
region with a mean log2 ratio of 1.132548, indicating a
triplicated segment of 557 kb with a description of arrtion/triplication
atient Tyson et al. (2005) Jehee et al. (2007)
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Figure 2 The result of chromosomal microarray testing. (Above) Gene View by Agilent Genomic Workbench (Agilent Technologies) is shown
in horizontal view; the X- and Y-axes indicate genomic location and a log2 ratio of the intensity, respectively. The region of genomic copy
number gain is shown by a blue-translucent rectangle with a mean log2 ratio of 1.132548 with the size of 557 kb in the 11q12.3 region. The gene
symbols discussed in the text are emphasized by red circles. (Bottom) The locations of the known CNVs are depicted.
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the International System for Human Cytogenetic Nomen-
clature (2013) (Figure 2). FISH analysis confirmed tripli-
cated signals in the interphase nucleus (Figure 3). One of
the targeted signals was stronger than the other on the
metaphase spreads of FISH, indicating triplication in 1 of
the 2 chromosome 11 homologues. Both parents’ samples
showed no abnormalities by chromosomal microarray
testing using 60K (data not shown), indicating de novo
occurrence of this triplication.Figure 3 FISH analysis by using BAC as the probes. Red signals
are markers of 11q25 labeled on RP11-469N6 (chr11:134,478,780-
134,651,287) and green signals are targeted markers of 11q12.3
labeled on RP11-163K24 (chr11:62,514,291-62,691,426). In the
interphase nucleus, 4 green signals are noted, confirming the
triplication of the targeted region. One of the targeted green signals
of the metaphase (arrow) is stronger than the other (arrowhead),
indicating the triplication at the same chromosome 11.Discussion
Compared to the location of the triplication that resulted
from DUP-TRP/INV-DUP, the triplicated region identi-
fied in the present study was not embedded within the
duplicated segments and there was no duplicated region
around the triplicated segment (Figure 2). Therefore, the
breakpoints caused by this triplication would be the
same among all fragments. Such small triplications that
are not embedded within duplicated segments are rare,
and we were able to identify similar cases in patients
with Parkinson’s disease associated with triplications in
the region of the synuclein alpha gene (SNCA) in the
literature [9]. In such cases, triplicated regions, including
SNCA, are not embedded within duplication. Because
the triplicated region identified at 11q12.3 was quite
small, we failed to confirm the insertion orientations of
the triplicated segments using FISH analysis (data not
shown). Due to the existence of many CNVs in thisregion (Figure 4), it was challenging to confirm the
breakpoints of the triplications using polymerase chain
reaction-based methods as mentioned in the introduc-
tion. Therefore, presently, the insertion orientations of
the triplicated segments remain unknown.
Triplication identified in this study
Figure 4 Genomic map viewed using the UCSC genome browser. Triplicated region of the patient (a light blue bar) is depicted on the UCSC
genome browser. DECIPHER #253705 is indicated by a blue bar that shows the duplication previously reported by Tyson et al. Three overlapping
duplications (blue bars) are included in the ISCA database.
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synostoses, a congenital heart defect, and developmental
delay [10]. Cytogenetic analyses identified a mosaic
existence of a large duplication of 11q11-q13.3 in that
case. Because the duplicated region included theTable 2 The genes he genes included in the SRO
Gene Symbol Function
1 ZBTB3 zinc finger and B
2 POLR2G polymerase (RNA
3 TAF6L TAF6-like RNA po
4 TMEM179B transmembrane p
5 TMEM223 transmembrane p
6 NXF1 nuclear RNA exp
7 STX5 syntaxin 5
8 WDR74 WD repeat dom
9 SNHG1 small nucleolar R
10 SLC3A2 solute carrier fam
11 CHRM1 cholinergic recep
12 SLC22A6 solute carrier famfibroblast growth factor 3 gene (FGF3) and fibroblast
growth factor 4 gene (FGF4), Jehee et al. discussed the
possibility that the gene dosage effects of these genes
resulted in the onset of craniosynostosis [10]. Although
the triplicated region identified in the present study wasTB dom ain containing 3
) II (DNA directed) polypeptide G





NA host gene 1 (non-protein coding)
ily 3 (activators of dibasic and neutral amino acid transport), member 2
tor muscarinic 1
ily 22 (organic anion transporter), member 6
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[10], the present patient did not show any symptoms of
craniosynostosis and the candidate genes, FGF3 and
FGF4, were not included in the triplicated region be-
cause of the extremely small size of the aberrant region.
When we analyzed the International Standard for
Cytogenomic Arrays (ISCA) database (https://www.
iscaconsortium.org/), we found that 3 duplications
were included in this region (Figure 4). Because the
ISCA database includes no clinical information, we
were unable to compare the phenotypic features of
our patient with those of others; however, the exist-
ence of similar duplications in this region would sug-
gest that the region may be prone to rearrangement
as a result of its structural nature. The DECIPHER
database (http://decipher.sanger.ac.uk/) showed only 1
overlapping duplication (chr11:62,514,284-65,140,178) in
the 11q12.3 region in a patient (DECIPHER #253705).
This patient had mild-to-moderate intellectual disability
and other complications that had already been reported
by Tyson et al. [11]. The common phenotypic features be-
tween our patient and the previously reported patients in-
clude brain developmental delay, finger abnormalities
(including arachnodactuly, camptodactyly, brachydactyly,
clinodactyly, and broad thumbs), and preauricular pits
[10,11] (Table 1). Therefore, we believe that the genes re-
sponsible for brain developmental delay and the
connective tissue abnormalities are located within the
shortest region of overlap (SRO) (Table 2). With regard to
the genes responsible for neurological features, including
developmental delay and hypotonia, Tyson et al. listed the
reticulon 3 gene (RTN3) as the candidate gene because of
its highest level of expression in the brain [11]. However,
RTN3 is not included within the triplicated region in the
present patient.
Alternatively, the syntaxin 5 gene (STX5) and the cho-
linergic receptor muscarinic 1 gene (CHRM1) (Table 2),
in the SRO may be related to the neurological features
of these 2 patients because of their functional relevance
to the central nervous system. STX5 encodes a member
of the syntaxin or t-SNARE (target-SNAP receptor)
family [12]. These proteins are found on cell mem-
branes and serve as targets for v-SNAREs (vesicle-SNAP
receptors), permitting specific synaptic vesicle docking
and fusion [13,14]. CHRM1 is reported to have some
relevance to neuronal functions. Muscarinic receptors
regulate several effects of acetylcholine in the central
and peripheral nervous system. The results of CHRM1-
null mutant mice investigations suggested that the M1
receptor is specifically involved in memory processes
for which the cortex and hippocampus interact [15].
Additionally, the functional relevance of CHRM1 in
schizophrenia and depressive disorders has been sug-
gested [16,17].Since the 1998 review that coined and defined the
term “genomic disorders” [18], a multitude of genomic
disorders caused by genomic rearrangements have been
identified [19], and many of them manifest neurological
features, including mental impairments, autistic features,
and psychiatric disorders [20,21]. This finding is because
there are many dosage-sensitive genes related to nervous
system functions. Additionally, there is disputable evi-
dence that CNVs can play a role in the pathogenesis of
neurodevelopmental and neurodegenerative disorders
[22]. In the present study, we proposed potential candi-
date genes for developmental delay; however, it is difficult
to determine which genes contribute to the connective
tissue involvement, including distinctive facial findings,
finger abnormalities, and pre-auricular tags seen in the
patients with genomic copy number gains of 11p12.3.
Methods
Blood samples were collected upon approval of the eth-
ics committee of our institution. A patient’s karyotype
was analyzed using the conventional G-banding tech-
nique at 400–500 band resolution. Genomic DNA was
extracted from blood samples using QIAamp DNA
extraction kit (QIAGEN, Hilden, Germany) and was sub-
sequently evaluated. Chromosomal microarray testing was
performed using Agilent Human Genome microarray 60K
(Agilent Technologies, Santa Clara, CA), as described pre-
viously [23]. Extracted data was analyzed using Agilent
Genomic Workbench ver. 6.5 (Agilent Technologies).
Metaphase spreads prepared using the patients’ blood
samples were used for FISH analyses to confirm the
results of chromosomal microarray testing. The bac-
terial artificial clones (BAC), RP11-469N6 and RP11-
163K24, were selected from the UCSC genome browser
(http://genome.ucsc.edu/) for use as probes. Both parental
samples were obtained and analyzed using chromosomal
microarray testing with a 60K array to confirm whether
the aberration identified on the patient was de novo.
Consent
Written informed consent was obtained from the patient’s
family.
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